Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...
The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...
Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how politics will impact innovation long term.
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, ...
Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...
In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...
US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...
Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...
Money Talks News on MSN
New pancreatic cancer treatment tracks tumors through your entire body
Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in ...
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback